Xin Lang Cai Jing·2025-10-16 07:28Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a significant overseas revenue share [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and has both A and H share financing platforms [2]. - The main business segments include heparin raw materials, low molecular weight heparin products, and biopharmaceutical CDMO services [7]. - As of June 30, 2025, the company reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit of 422 million yuan, down 36.44% year-on-year [7]. Financial Performance - The overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed in the last three years [8]. Market Activity - On October 16, Haiprui's stock price decreased by 0.17%, with a trading volume of 45.1938 million yuan and a turnover rate of 0.31%, resulting in a total market capitalization of 17.299 billion yuan [1]. - The stock's average trading cost is 11.57 yuan, with current price fluctuations between resistance at 12.33 yuan and support at 11.16 yuan [6]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 7.29% to 26,300, with no circulating shares per person [7]. - The eighth largest shareholder is Hong Kong Central Clearing Limited, holding 11.3176 million shares, an increase of 6.3765 million shares from the previous period [9].